Meet the Genedata
Biopharma Community
Genedata Biopharma Partner Symposium in Basel, Switzerland: March 23–24, 2022
The Genedata Biopharma Partner Symposium is a unique interdisciplinary event at the interface between biopharma R&D and IT. Presentations and discussions will focus on innovative applications and new industry requirements, such as novel molecular formats (e.g., multispecifics, TCRs, and CARs), MS-based multi-attribute methods (MAM), NGS, molecular-based patient profiling, and increasing automation and standardization in biopharmaceutical R&D.
Leading biopharma companies will show how groups have set up, operate, and use Genedata solutions to transform their biotherapeutics research & development and how this results in increased efficiency and throughput. The symposium brings together people working in all areas of biopharma:
- Discovery—Screening, selection, engineering, and validation
- Development—Characterization, optimization, and cell-line engineering
- Production—Bioprocessing, biosafety, and QC
- Translational Science—Patient profiling and integrative (pre-)clinical research
- IT—Infrastructure, networking, and integration
Participants can also take part in targeted break-out sessions, discuss product development roadmaps, and join poster and demo sessions to discover how the Genedata Biopharma Platform is streamlining processes and increasing efficiency throughout biopharmaceutical research, development, and production.
In addition to the scientific program, there will be an evening social networking event and dinner.
Agenda 2022
| Day 1 – Wednesday, March 23, 2022 | |||
|---|---|---|---|
| Plenary Session | |||
| 8:30–9:00 | Registration & Welcome Coffee Hyperion Hotel 3rd Floor, Messeplatz 12, Basel, Switzerland | ||
| 9:00–9:10 | Opening Remarks Jana Hersch, Ph.D., Scientific Consultant, Genedata, Basel, Switzerland | ||
| 9:10–9:30 | Challenges in Digitalizing Biopharma R&D Othmar Pfannes, Ph.D., CEO, Genedata, Basel, Switzerland | ||
| 9:30–10:00 | Biologics Discovery at Novartis – Synergies Within and Beyond the Biopharma Platform Markus Kroemer, Ph.D., Associate Director Data Science, Novartis, Basel, Switzerland Björn Hüber, Team Leader Data Management, Novartis – NIBR Biologics Center, Basel, Switzerland | ||
| 10:00–10:30 | AstraZeneca’s 10 Years of Partnership with Genedata – Innovation, Efficiency, Reliability Jonathan Wingfield, Ph.D., Principal Scientist, AstraZeneca, Cambridge, UK | ||
| 10:30–11:00 | Break | ||
| Break-out Sessions | |||
| BIOLOGICS Biologics Discovery | SCREENER Discovery Screening | EXPRESSIONIST Mass-Spec Analytics | |
| 11:00–11:30 | Enabling Discovery – Enriching Data Analysis for Biologics at Merck Sameh Eid, Ph.D., Principal Scientist, Research Informatics, Merck Healthcare KGaA, Darmstadt, Germany | Implementation of Genedata Screener for Drug Discovery at Lundbeck Alexander Cahlin, Research Assistant, Lundbeck, Valby, Denmark | From MS-Based Characterization to Automated Data Treatment for ADCs and Oligonucleotides Anthony Ehkirch, Ph.D., Principal Scientist, Novartis, Basel, Switzerland |
| 11:30–12:00 | Janssen's High-Throughput Biopharma R&D in the Digital Age Kimberly Munsell, Senior CSV and Compliance Manager, Janssen, Spring House, PA, USA | Digitalization of R&D at Roche – Challenges, Progress, and Outlook Romel Bobby, Ph.D., Senior Scientist, Roche, Basel, Switzerland Anastasios Moresis, Ph.D., Senior Scientist, Roche, Basel, Switzerland | High-Throughput Protein Analysis and Reporting in Industrial Biotechnology Anders Giessing, Ph.D., Senior Scientist, Novozymes, Bagsvaerd, Denmark |
| 12:00–13:30 | Lunch | ||
| 13:30–14:00 | Pfizer’s New mRNA Workflows for Vaccines and Therapeutics Joel Bard, Ph.D., Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA | Application of High Throughput Cellular Thermal Shift Assays (HT-CETSA) in Early Drug Discovery Felix Baerenz, Ph.D., Lab Head, In Vitro Biology, Sanofi, Frankfurt, Germany | RP-MAM and HILIC-MAM – A Combined Approach for Highly Glycosylated Fusion Protein Melanie Jakobczyk, Associate Scientist, Biotech Process Sciences, Merck Healthcare, Corsier-sur-Vevey, Switzerland |
| 14:00–14:30 | Analytical Workflow Integration in Genedata Biologics Samuel Cheng, Ph.D., IS Lead Business Consultant, IT RDM Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA | High-Throughput Covalent Fragment Screening with MALDI Mass Spectrometry Don Nguyen, Ph.D., High Throughput Mass Spectrometrist, Bioassay Automation, Discovery Pharmacology, Merck Healthcare KGaA, Darmstadt, Germany | HCP Analysis of Scale Down Model Processes William Burkitt, Ph.D., Associate Director, UCB, Slough, UK |
| 14:30–15:00 | Genedata Biologics at Takeda – Adoption and Building Tools for Data Upload Prashanth Vishwanath, Ph.D., Associate Director, Global Biologics, Takeda, Cambridge, MA, USA | A Hitchhiker’s Guide to the Biophysics Galaxy – Positioning SPR on the Drug Discovery Map Christine Genick, Ph.D., Principal Scientist II, Lab Head, Novartis, Basel, Switzerland | Open Discussion The Future of Mass Spectrometry in the Biopharma Industry |
| Plenary Session | |||
| 15:10–15:40 | Utilizing Translational Data Science to Improve Drug Development and Treatment of Patients Sriram Sridhar, Ph.D, Director, Translational Data Science, Genmab, Princeton, NJ, USA | ||
| 15:40–16:00 | Break | ||
| 16:00–18:00 | Demo & Poster Session Meet the Experts – Check out our demos and view posters. Demos are approximately 5–10 minutes and will be repeated on demand throughout the session | ||
| 19:30–21:30 | Group Dinner | ||
| Day 2 – Thursday, March 24, 2022 | ||||
|---|---|---|---|---|
| Plenary Session | ||||
| 8:30–9:00 | Welcome Coffee | |||
| 9:00–9:15 | Opening Remarks Jana Hersch, Ph.D., Scientific Consultant, Genedata, Basel, Switzerland | |||
| 9:15–9:45 | Sharing Experiences with the Implementation of Genedata BioPharma at Genmab Rik Rademaker, Ph.D., Director Cell and Molecular Sciences, Genmab, Utrecht, The Netherlands | |||
| Break-out Sessions | ||||
| BIOLOGICS Biologics Discovery | SCREENER Discovery Screening | BIOPROCESS Bioprocess Development | SELECTOR NGS-Driven Biosafety | |
| 9:45–10:15 | The Evolution of Novartis' Biologics Platform – Technical Developments Desmond Fox, NX Business Analyst, Novartis – NIBR Biologics Center, Basel, Switzerland Drazen Nadoveza, Ph.D., Senior Principal Software Engineer, Novartis – NIBR Biologics Center, Basel, Switzerland | Implementation of Genedata Screener at Servier Anne-Laure Ong, Screening Team Leader, Servier, Croissy, France | NGS-Based Methods for the Characterization of Gene Knockouts Rico Uhler, Ph.D., Group Manager Automation and Data Management, Octapharma, Heidelberg, Germany | |
| 10:15–10:45 | Break | |||
| 10:45–11:15 | Genedata Biologics at Charles River – Supporting End-to-End Biologics Discovery Maurice Brozzo, Ph.D., European Antibody Discovery Business Development Manager, Charles River Laboratories, Zurich, Switzerland | Evotec’s RT-qPCR Data Analysis Workflow for Accelerated RNA-Targeted Drug Discovery Romain Chassefeyre, Ph.D., Project and Team Lead, Evotec, Toulouse, France Xavier Marechal, Ph.D., Project and Team Lead, Evotec, Toulouse, France | Data View Customization and Report Automation with Genedata Bioprocess Markus Sanna, Manager Digital Data Excellence and IT Services, Sartorius Stedim Cellca GmbH, Ulm, Germany | Validation Data to Support NGS Purity Testing of Veterinary Master Seeds Blandine de Saint-Vis, Ph.D., Global MSAT Bio-Analytics – Senior Scientist, Boehringer Ingelheim Animal Health, Saint-Priest, France |
| 11:15–11:45 | Genedata Biologics – Benchling ELN Integration at Agenus Andreas Arnell, Laboratory Informatics Manager, Agenus, Cambridge, UK | AI at Your Fingertips – Automation of High Content Screening Analysis with Genedata Imagence 5.0 Cameron Scott, Scientific Account Manager, Genedata, Basel, Switzerland | Genedata in AgTech – From Clone Pool to Food Protection Dominique Vlieghe, Ph.D., Data and Information Manager, Biotalys, Ghent, Belgium | A Newly Identified Small RNA Regulates NGNA Sialylation in CHO Cells Moritz Schmidt, Ph.D., Head of Laboratory Molecular Biology, Boehringer-Ingelheim, Ulm, Germany |
| 11:45–13:15 | Lunch | |||
| Plenary Session | ||||
| 13:15–13:45 | Genedata Biologics-Supported Workflows for HT Screening of Multi-Specifics: Recent Advances and Future Perspectives Dilyana Dimova, Ph.D., Senior Data Scientist, Sanofi, Frankfurt, Germany | |||
| 13:45–14:15 | Genedata Current and Future Solutions for Automation Laboratories Sascha Fischer, Business Development Automation, Genedata, Basel, Switzerland | |||
| 14:15–14:45 | Path to Precision Medicine – Connecting People and Data Tamas Rujan, Head of Genedata Profiler, Business, Basel, Switzerland Marc Flesch, Ph.D., Head of Genedata Profiler, Product, Munich, Germany | |||
| 14:45–15:00 | Closing Remarks Othmar Pfannes, Ph.D., CEO, Genedata, Basel, Switzerland | |||
| 15:00–15:30 | Post Symposium Open Discussion & Farewell Coffee | |||
| End of Symposium | ||||
Previous Genedata symposia have included customer presentations from partners including
The format with the expert demo stations worked particularly well and the timings of the presentations/breaks was spot on in my opinion. As always content and attendance was great. Congratulations and look forward to the next one.
Past Symposium Attendee
The discussion in the breaks and after the presentations were really informative. It’s very interesting to see how other companies are working with Genedata.
Past Symposium Attendee
User companies presenting on their digitalization journey made me feel that we are not much behind. Industry-wide use of Genedata was confirmed which increased company reputation in my eyes.
Past Symposium Attendee
I found the event really useful, meeting other companies and looking at how Biologics is being implemented. There were some extremely exciting topics and discussions – very insightful.
Past Symposium Attendee
It was really good – will be leaving inspired with loads of ideas on how to use the system in even better ways.
Past Symposium Attendee
Genedata is a critical software for our work so it’s great to come to the partner symposium and have a voice in how the product develops.
Past Symposium Attendee
Very good, quite diverse presentations, nice talks with different users. We are happy with what we learn here.
Past Symposium Attendee